Effects of Electromechanical Gait Trainer on Endurance, Fatigue and Daily Life Autonomy in Patients With Multiple Sclerosis: a Randomized Control Trial

CompletedNot a drug-phase studyRelapsing MSNCT01564511

What it found

No results found

We found no results in the registry or in papers.

This trial finished 14 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

  • Gait trainer treatment

Placebo

  • Conventional treatment

What it measured

Main measures

  • 6-minute Walking Test

    All patients enrolled in the study will be evaluated before the beginning (baseline time 0) of treatment and after the end (after 6 weeks) of the treatment.

    Walking and mobility

Other measures (6)

  • 10-meter Walking Test

    All patients enrolled in the study will be evaluated before the beginning (baseline time 0) of treatment, after the end (after 6 weeks) of the treatment and at 1 month FU

    Walking and mobility
  • Falls efficacy scale score

    All patients enrolled in the study will be evaluated before the beginning (baseline time 0) of treatment, after the end (after 6 weeks) of the treatment and at 1 month FU

    FatigueWalking and mobility
  • Spatio-temporal gait analysis

    All patients enrolled in the study will be evaluated before the beginning (baseline time 0) of treatment, after the end (after 6 weeks) of the treatment and at 1 month FU

    Walking and mobility
  • Static balance assessment

    All patients enrolled in the study will be evaluated before the beginning (baseline time 0) of treatment, after the end (after 6 weeks) of the treatment and at 1 month FU

    Walking and mobility
  • Measure of energy cost

    All patients enrolled in the study will be evaluated before the beginning (baseline time 0) of treatment, after the end (after 6 weeks) of the treatment and at 1 month FU

  • Hamilton Rating Scale for Depression

    All patients enrolled in the study will be evaluated before the beginning (baseline time 0) of treatment, after the end (after 6 weeks) of the treatment and at 1 month FU

    Mood and sleep

Who could take part

Relapsing MS · 30 to 60

Show the full criteria

Inclusion criteria

1. age between 30 and 60 years 2. Expanded Disability Status Scale (EDSS) score 2.0≥ x ≤ 4.0 3. Mini Mental State Evaluation (MMSE) score ≥ 24 4. absence of heart problems 5. ability to maintain standing position without aids for at least 1 minute 6. ability to walk independently for at least 15 metres 7. absence of concurrent neurological or orthopaedic diseases that interfere with deambulation.

Exclusion criteria

1. disease recurrence that worsens significantly during the 3 months prior to recruitment 2. pharmacological therapy not well defined 3. performance of any type of rehabilitation treatment in the month prior to recruitment 4. presence of other concurrent neurological or orthopaedic diseases involving the lower limbs and/or interfering with standing position and/or walking

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

Multiple Sclerosis is a very disabling disorder in young adult patients leading to an important limitation in daily life activities and social participation. Among of the different causes of disability in MS patients gait impairments, fatigue and balance disorders can be considered as the main concerns. Thus, gait restoration in patients with MS is the one of the primary objective of rehabilitation and often influences whether a patient can return home or to work. Even if potentially innovative treatments like treadmill training have been proposed, nowadays the role of robotic assisted locomotion rehabilitation has not been extensively studied in patients with MS.

Papers

Loading reviews and guidelines…

History

    1. Started

      Nov 2011

    2. Main results due

      Feb 2012

    3. Finished

      Dec 2012

    Assembled by software from public sources.